CN
Search Within
T2577
应用筛选条件
关键词:'T2577'
显示 1-30 共 297 条结果 关于 "T2577" 范围 论文
Olga Piskareva et al.
Cancer letters, 364(2), 142-155 (2015-05-12)
Neuroblastoma is a challenging childhood malignancy, with a very high percentage of patients relapsing following acquisition of drug resistance, thereby necessitating the identification of mechanisms of drug resistance as well as new biological targets contributing to the aggressive pathogenicity of
Chih-Jung Yao et al.
Integrative cancer therapies, 13(6), 541-554 (2014-11-02)
High-grade gliomas are the most common and invasive malignant brain tumors in adults, and they are almost universally fatal because of drug resistance and recurrence. In spite of the progress in adjuvant therapy (like temozolomide) and irradiation after surgery, no
Jara Majuelos-Melguizo et al.
Oncotarget, 6(7), 4790-4803 (2015-01-13)
Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and one of the most aggressive cancers. PARP-1 is a nuclear protein involved in multiple facets of DNA repair and transcriptional regulation. In this study we dissected the
Sauradeep Sinha et al.
Advanced healthcare materials, 12(1), e2202147-e2202147 (2022-10-15)
Glioblastoma multiforme (GBM) is the most prevalent and aggressive brain tumor in adults. Hydrogels have been employed as 3D in vitro culture models to elucidate how matrix cues such as stiffness and degradation drive GBM progression and drug responses. Recently
Richard D Carvajal et al.
JAMA, 311(23), 2397-2405 (2014-06-19)
Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting in mitogen-activated protein kinase pathway activation. To assess the efficacy of selumetinib, a selective, non-adenosine triphosphate competitive inhibitor of MEK1 and MEK2, in uveal melanoma. Randomized, open-label, phase 2
Mingcong Li et al.
Journal of molecular neuroscience : MN, 56(4), 949-955 (2015-04-15)
The development of novel therapeutic strategies for glioma requires the identification of molecular targets involved in malignancy. Pygopus (Pygo) is a new discovered and specific downstream component of canonical Wnt signaling. Our previous study has demonstrated that Pygo2 is highly
Nu Zhang et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 18(21), 5961-5971 (2012-09-15)
Recurrent glioblastoma multiforme (GBM) is characterized by resistance to radiotherapy and chemotherapy and a poor clinical prognosis. In this study, we investigated the role of the oncogenic transcription factor FoxM1 in GBM cells' resistance to alkylator temozolomide (TMZ) and its
Abdel Nasser Hosein et al.
Journal of neuro-oncology, 122(2), 263-271 (2015-02-05)
Glioblastoma multiforme (GBM) has nearly uniformly fatal with a median survival of less than 2 years. While there have not been any novel anti-GBM therapeutics approved for many years, there has been the gradual accumulation of clinical data suggesting that
C-H Fan et al.
Cell death & disease, 4, e876-e876 (2013-10-26)
Temozolomide (TMZ) is an alkylating agent currently used as first-line therapy for gliomas treatment due to its DNA-damaging effect. However, drug resistance occurs, preventing multi-cycle use of this chemotherapeutic agent. One of the major mechanisms of cancer drug resistance is
Michael Weller et al.
International journal of cancer, 134(10), 2437-2447 (2014-03-13)
The epidermal growth factor receptor vIII mutant (EGFRvIII) is found in ~50% of all EGFR-amplified glioblastomas and constitutes a tumor-specific therapeutic target. To assess molecular testing approaches and the prognostic role of EGFRvIII in patients treated according to current standards
Edward B Reilly et al.
Molecular cancer therapeutics, 14(5), 1141-1151 (2015-03-04)
Despite clinical efficacy, current approved agents targeting EGFR are associated with on-target toxicities as a consequence of disrupting normal EGFR function. MAb 806 is a novel EGFR antibody that selectively targets a tumor-selective epitope suggesting that a mAb 806-based therapeutic
Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma.
Stephen W Clark et al.
Neurology, 81(1), 93-94 (2013-05-21)
Diane Palmieri et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(10), 2727-2739 (2014-03-19)
Brain metastases of breast cancer cause neurocognitive damage and are incurable. We evaluated a role for temozolomide in the prevention of brain metastases of breast cancer in experimental brain metastasis models. Temozolomide was administered in mice following earlier injection of
Yunsong Tong et al.
Journal of medicinal chemistry, 52(21), 6803-6813 (2009-11-06)
Small molecule inhibitors of PARP-1 have been pursued by various organizations as potential therapeutic agents either capable of sensitizing cytotoxic treatments or acting as stand-alone agents to combat cancer. As one of the strategies to expand our portfolio of PARP-1
Sung Su Kim et al.
Biochemical and biophysical research communications, 440(4), 658-663 (2013-10-12)
Hypoxia-induced alterations in the cellular redox status play a critical role in the development of hypoxia-induced chemoresistance in cancer cells. Human biliverdin reductase (hBVR), an enzyme involved in the conversion of biliverdin into bilirubin in heme metabolism, was recently identified
Mehmet Taspinar et al.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 34(3), 1935-1947 (2013-03-23)
Temozolomide (TMZ) is commonly used in the treatment of glioblastoma (GBM). The MGMT repair enzyme (O (6)-methylguanine-DNA methyltransferase) is an important factor causing chemotherapeutic resistance. MGMT prevents the formation of toxic effects of alkyl adducts by removing them from the
Jie Wang et al.
Cancer chemotherapy and pharmacology, 72(1), 147-158 (2013-05-07)
Recent studies have reported that miR-181b contributes to chemoresistance in several cancer types and functions as a tumor suppressor in glioma. This study aimed to explore whether miR-181b could enhance the chemotherapeutic effect of temozolomide in glioma cells and sought
Ping Shi et al.
Frontiers in oncology, 12, 837589-837589 (2022-04-02)
Tumor Treating Fields (TTFields) are low-intensity, alternating intermediate-frequency (200 kHz) electrical fields that extend survival of glioblastoma patients receiving maintenance temozolomide (TMZ) chemotherapy. How TTFields exert efficacy on cancer over normal cells or interact with TMZ is unclear. Primary cilia are
Stephanie A Nguyen et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(18), 4894-4903 (2014-08-01)
The current standard of care for glioblastoma (GBM) involves a combination of surgery, radiotherapy, and temozolomide chemotherapy, but this regimen fails to achieve long-term tumor control. Resistance to temozolomide is largely mediated by expression of the DNA repair enzyme MGMT;
Christopher A Barker et al.
International journal of radiation oncology, biology, physics, 86(3), 504-509 (2013-03-26)
Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, and it can modulate the biologic effects of radiation therapy (RT). We investigated whether VA use during RT
Jesse Liang et al.
Journal of visualized experiments : JoVE, (184) (2022-07-06)
Cell-matrix interactions mediate complex physiological processes through biochemical, mechanical, and geometrical cues, influencing pathological changes and therapeutic responses. Accounting for matrix effects earlier in the drug development pipeline is expected to increase the likelihood of clinical success of novel therapeutics.
Vincent Gleize et al.
Annals of neurology, 78(3), 355-374 (2015-05-29)
CIC gene is frequently mutated in oligodendroglial tumors with 1p19q codeletion. However, clinical and biological impact remain poorly understood. We sequenced the CIC gene on 127 oligodendroglial tumors (109 with the 1p19q codeletion) and analyzed patients' outcome. We compared magnetic
K Mihajluk et al.
Cancer letters, 458, 29-38 (2019-05-28)
High grade gliomas (HGGs) are aggressive primary brain tumours with local invasive growth and poor clinical prognosis. Clinical outcome is compounded by resistance to standard and novel therapeutics. We have evaluated reformulated aspirin (IP1867B) alone and in combination with conventional
Viviane Aline Oliveira Silva et al.
Molecules (Basel, Switzerland), 24(23) (2019-11-28)
The identification of signaling pathways that are involved in gliomagenesis is crucial for targeted therapy design. In this study we assessed the biological and therapeutic effect of ingenol-3-dodecanoate (IngC) on glioma. IngC exhibited dose-time-dependent cytotoxic effects on large panel of
Yong Wang et al.
Neurology India, 61(3), 260-264 (2013-07-19)
Primary central nervous system lymphoma (PCNSL) is an aggressive extranodal non-Hodgkin's lymphoma limited to the CNS. Treatment of PCNSL with high-dose methotrexate (HD-MTX)-based chemotherapy and whole-brain radiotherapy (WBRT) is associated with high rates of relapse and severe treatment-related neurotoxicity. To
Antonin Dréan et al.
Journal of neuro-oncology, 144(1), 33-41 (2019-06-15)
Glioblastoma (GBM) is the most common and aggressive primary brain cancer in adults. Few cytotoxic chemotherapies have been shown to be effective against GBM, due in part to the presence of the blood-brain barrier (BBB), which reduces the penetration of
Dan Jin et al.
PloS one, 14(10), e0223555-e0223555 (2019-10-11)
Cyclin-dependent kinases 4 and 6 (CDK4/6) play critical roles in the G1 to S checkpoint of the cell cycle and have been shown to be overactive in several human cancers. Small-molecule inhibitors of CDK4/6 have demonstrated significant efficacy against many
Yolande Berthois et al.
Cancer biology & therapy, 15(7), 938-950 (2014-04-24)
Glioblastoma multiforme (GBM) is the most common primary brain tumor and is among the deadliest of human cancers. Dysregulation of microRNAs (miRNAs) expression is an important step in tumor progression as miRNAs can act as tumor suppressors or oncogenes and
Anna L Koessinger et al.
Scientific reports, 10(1), 15361-15361 (2020-09-23)
Despite extensive research, little progress has been made in glioblastoma therapy, owing in part to a lack of adequate preclinical in vivo models to study this disease. To mitigate this, primary patient-derived cell lines, which maintain their specific stem-like phenotypes
[Regulation of MGMT and application for the therapy to attenuate the chemoresistance].
Shinji Kohsaka et al.
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 8, 346-352 (2013-03-22)
1/10